Celera forms pact with Bristol-Myers Squibb:
This article was originally published in Clinica
Celera Diagnostics has linked up with Bristol-Myers Squibb (BMS) to study genes that may be useful for diagnosing and treating cardiovascular disease and diabetes. Under the terms of an agreement between the two firms, BMS will receive exclusive rights to develop and market drugs for cardiovascular disease and diabetes based on therapeutic targets identified by the studies conducted by Celera. Celera will retain exclusive rights to develop and market diagnostic products. Alameda, California-based Celera recently formed deals with Laboratory Corporation of America and Quest Diagnostics (see Clinica 1028, p 22).